Funder
Isfahan University of Medical Sciences
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference24 articles.
1. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler J 17:1225–1230
2. Bichuetti DB, de Oliveira EML, Oliveira DM, de Souza NA, Gabbai AA (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67:1131–1136
3. Carreón-Guarnizo E, Hernández-Clares R, Palazón-Cabanes B, Carrasco-Torres R, Salgado G, Jimenez-Veiga J, León-Hernández A, Martín-Fernández JJ, Meca-Lallana J (2015) Safety of rituximab as first-line therapy in neuromyelitis optica (NMO) and NMO-spectrum disorders: five years of experience (P5. 264). Neurology 84(P5):264
4. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A (2011) Azathioprine tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659–666
5. Cree B, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272
Cited by
156 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献